Trial Profile

Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; Cisplatin
Indications Oropharyngeal cancer; Squamous cell cancer
Focus Biomarker; Therapeutic Use

Most Recent Events

26 Oct 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2026.
19 Nov 2022 Results of secondary analysis, published in the Cancer
13 Sep 2022 Results of sub study (n=381) assessing Quality of life in patients with oropharyngeal cancer treated with with either cisplatin or cetuximab presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com